IgM-κ 및 IgA-λ 이중클론감마병증을 가진 림프형질세포림프종/발덴스트롬마크로글로불린혈증 1례

키워드

참고문헌 (24)

1. The Korean Society of Hematology, "Hematology", pp.367~ (2018), Panmun Education
2. Swerdlow SH, "WHO classication of tumours of haematopoietic and lymphoid tissues", pp.236~ (2017), IARC
3. 강지훈, "Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience", Blood Research, 53(3), pp.189~197 (2018), 대한혈액학회
4. King RL, "Lymphoplasmacytic lymphoma with a non-IgM paraprotein shows clinical and pathologic heterogeneity and may harbor MYD88 L265P mutations", Am J Clin Pathol, 145, pp.843~851 (2016)
5. Cao X, "Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression", Leuk Lymphoma, 57, pp.1104~1113 (2016)
6. 신상용, "Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma", Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas, 2016, pp.51(3), 181~186[DOI]
7. Wadhwa J, "Lymphoplasmacytic lymphoma", JIPMER Journal of Cancer, 4, pp.52~54 (2014)
8. García-García P, "Biclonal gammopathies : retrospective study of 47 patients", Rev Clin Esp, 215, pp.18~24 (2015)
9. Naderi N, "Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia", Arch Pathol Lab Med, 137, pp.580~585 (2013)
10. Kumar SK, "Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 15, pp.230~269 (2017)
11. Kapoor P, "Diagnosis and management of Waldenström macroglobulinemia : Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy(mSMART)Guidelines 2016", JAMA Oncol, 3, pp.1257~1265 (2017)
12. Schuster SR, "IgM multiple myeloma : disease denition, prognosis, and differentiation from Waldenstrom’s macroglobulinemia", Am J Hematol, 85, pp.853~855 (2010)
13. Wang E, "Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia : sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual", Hum Pathol, 43, pp.1135~1141 (2012)
14. Rossi D, "Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis", Hematology Am Soc remato Educ Program, 2014, pp.113~118 (2014)
15. Kyle RA, "Long-term follow-up of monoclonal gammopathy of undetermined signicance", N Engl J Med, 378, pp.241~249 (2018)
16. McMaster ML, "Novel aspects pertaining to the relationship of Waldenström’s macroglobulinemia, IgM monoclonal gammopathy of undetermined signicance, polyclonal gammopathy, and hypoglobulinemia", Clin Lymphoma Myeloma, 9, pp.19~22 (2009)
17. Murphy K, "Janeway’s Immunobiology", pp.167~ (2009), Garland Science, Taylor & Francis Group, LLC
18. Treon SP, "MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia", N Engl J Med, 367, pp.826~833 (2012)
19. Willenbacher W, "Improved accuracy of discrimination between IgM multiple myeloma and Waldenström macroglobulinemia by testing for MYD88 L265P mutations", Brit J Haematol, 161, pp.902~904 (2013)
20. Xu L, "MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specic polymerase chain reaction", Blood, 121, pp.2051~2058 (2013)
21. Jiménez C, "MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia", Leukemia, 27, pp.1722~1728 (2013)
22. Ondrejka SL, "MYD88 L265P somatic mutation : its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders", Am J Clin Pathol, 140, pp.387~394 (2013)
23. Shendure J, "Next-generation DNA sequencing", Nat Biotechnol, 26, pp.1135~1145 (2008)
24. Schuster SC, "Next-generation sequencing transforms today’s biology", Nat Methods, 5, pp.16~18 (2008)

관련 논문AI추천